pateclizumab (RG7416) / Roche - LARVOL DELTA

Generation of aptamers for the selective detection and neutralization of soluble lymphotoxin alpha. (PubMed, Mol Ther Nucleic Acids) - "While monoclonal antibodies that can neutralize human LTα3 in vivo do exist (e.g., pateclizumab), their efficacy and subsequent use within the clinic have been limited...Using rational design, we optimize the sequences and show that LTa1 and LTa5 can significantly reduce LTa3-TNFR1 engagement-associated cytotoxicity in vitro, highlighting their future therapeutic potential. These data highlight aptamers for the future investigation of lymphotoxin signaling, limiting off-target impacts on other LT⍺3-dependent mechanisms."

Journal • Immunology • Inflammation • TNFRSF1A

Human Regulatory B Cells Prevent Effector CD4+CD25- T Cell Proliferation Though a Mechanism Dependent from Granzyme B and Lymphotoxin Alpha [Board No. D007] (ATC 2023) - "We report for the first time for a role of LTA in GZMB+Bregs as an enhancer of GZMB expression, and involved in the suppressive properties of GZMB+Bregs in human. The exact mechanism of LTA/GZMB function in this specific subset of Bregs remains to be determined."

Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Transplantation • CD4 • GZMB • IL2RA • ISG20

Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) in DMARD-IR patients: Results of a randomized, double-blind, placebo-controlled head-to-head phase 2 study with adalimumab (EULAR 2013) - Presentation time: 15.06.2013; 12:10; Abstract #SAT0110; P2, N=217; Sponsor: Genentech; NCT01225393; "Pateclizumab treatment of DMARD-IR RA patients was associated with modest improvement in the signs and symptoms of RA, and was inferior to adalimumab after 12 weeks of treatment. Statistically significant treatment effects of pateclizumab were only detected for the secondary endpoint of ACR20. Pateclizumab had a safety profile comparable to PBO in this Phase 2 study in DMARD-IR patients."

P2 data • Rheumatoid Arthritis

Roche Pharmaceuticals pipeline (Hoffmann-La Roche Ltd) - Removed from pipeline for development in RA

Discontinued • Rheumatoid Arthritis

The role of lymphotoxin in autoimmune disease (ASI 2012) - P1, N=65; NCT00888745; "In a randomized, double-blind, placebo-controlled phase I study of 65 patients with active RA, we show the safety and activity of pateclizumab. These data indicate that depleting Th1 and Th17 with anti LT mAb may be beneficial in the treatment of autoimmune disease."

P1 data • Rheumatoid Arthritis